PolyPeptide Group AG is a Pharmaceuticals company based in Switzerland, specializing in peptides and oligonucleotides. As an independent CDMO, PolyPeptide Group focuses on APIs and intermediates for therapeutic products. With a ESG risk rating score of 21.3, the company is considered to be at medium risk. Operating primarily in Europe and Asia, PolyPeptide Group AG is a leading player in the pharmaceutical industry.